Cost Saving Opportunities in NSCLC Therapy by Optimized Diagnostics

The (Con-) Fusion in ALK Diagnostics: When Food and Drug Administration–Approved Algorithms Fail

(2016) Jessica Jürgens et al.   JOURNAL OF CLINICAL ONCOLOGY

Routine molecular profiling of patients with NSCLC

(2016) Verena Schildgen et al.   LANCET

Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)

(2016) Fabrice Barlesi et al.   LANCET

Epidemiology of driver mutations in lung cancer in a German tertiary hospital in patients with testing indication

(2016) Verena Schildgen et al.   Personalized Medicine

Lung Adenocarcinoma Harboring Concomitant EGFR Mutation and EML4-ALK Fusion That Benefits From Three Kinds of Tyrosine Kinase Inhibitors: A Case Report and Literature Review

(2015) Ning Zhao et al.   Clinical Lung Cancer

Prognostic factors affecting survival in non-small cell lung carcinoma patients with malignant pleural effusions

(2015) Umut Sabri Kasapoglu et al.   Clinical Respiratory Journal

Treatment, overall survival, and costs in patients withALK-positive non-small-cell lung cancer after crizotinib monotherapy

(2015) A. Guérin et al.   CURRENT MEDICAL RESEARCH AND OPINION

Detection of EML4-ALK in Lung Adenocarcinoma Using Pleural Effusion with FISH, IHC, and RT-PCR Methods

(2015) Leilei Liu et al.   PLoS One

The EML4-ALK oncogene: targeting an essential growth driver in human cancer

(2015) Hiroyuki MANO   PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES

The Management and Costs of Locally Advanced or Metastatic Alk-Positive Non-Small Cell Lung Cancer in Greece

(2015) H Kousoulakou et al.   VALUE IN HEALTH

Combined point mutation in KRAS or EGFR genes and EML4–ALK translocation in lung cancer patients

(2014) Jessica Jürgens et al.   Future Oncology

Variations in Molecular Profile in NSCLC Can Be Analyzed Using Cytological Samples

(2014) Maria D. Lozano et al.   INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY

Cost Effectiveness of Crizotinib for Anaplastic Lymphoma Kinase–Positive, Non–Small-Cell Lung Cancer: Who Is Going to Blink at the Cost?

(2014) Ronan J. Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter ALK Testing in Non–Small-Cell Lung Cancer: Results of a Round Robin Test

(2014) Maximilian von Laffert et al.   Journal of Thoracic Oncology

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: A comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features

(2014) Yunjian Pan et al.   LUNG CANCER

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases

(2014) K. S. Mak et al.   NEURO-ONCOLOGY

Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects

(2014) Dana Olsen et al.   Frontiers in Oncology

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant

(2013) Ka-Fai To et al.   Journal of Thoracic Oncology

Large-Scale Screening and Molecular Characterization of EML4-ALK Fusion Variants in Archival Non–Small-Cell Lung Cancer Tumor Specimens Using Quantitative Reverse Transcription Polymerase Chain Reaction Assays

(2013) Tianhong Li et al.   Journal of Thoracic Oncology

Anaplastic lymphoma kinase (ALK) gene rearrangement in non-small cell lung cancer (NSCLC): Results of a multi-centre ALK-testing

(2013) Maximilian v. Laffert et al.   LUNG CANCER

Neue morphologische und molekulare Aspekte des Lungenkarzinoms

(2013) A. Warth et al.   PATHOLOGE

Improving HIV coreceptor usage prediction in the clinic using hints from next-generation sequencing data

(2012) N. Pfeifer et al.   BIOINFORMATICS

Geno2pheno[454]: A Web Server for the Prediction of HIV-1 Coreceptor Usage from Next-Generation Sequencing Data

(2012) Alexander Thielen et al.   INTERVIROLOGY

Role of molecular studies in the diagnosis of lung adenocarcinoma

(2012) Samuel A Yousem   MODERN PATHOLOGY

An expanded model of HIV cell entry phenotype based on multi-parameter single-cell data

(2012) Katarzyna Bozek et al.   Retrovirology

Hierarchical Bayes Model for Predicting Effectiveness of HIV Combination Therapies

(2012) Jasmina Bogojeska et al.   Statistical Applications in Genetics and Molecular Biology

Prinzipien der individualisierten, zielgerichteten Therapie am Beispiel des nicht-kleinzelligen Bronchialkarzinoms

(2011) J Wolf   DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT

Performance of Different Mono- and Multiplex Nucleic Acid Amplification Tests on a Multipathogen External Quality Assessment Panel

(2011) K. Loens et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

(2011) Alice T Shaw et al.   LANCET ONCOLOGY

Personalisierte medikamentöse Therapie des fortgeschrittenen nichtkleinzelligen Lungenkarzinoms

(2011) J. Köhler et al.   Onkologe

Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF02341066) in an ALK Translocation-Positive Patient with Non-small Cell Lung Cancer

(2010) Sai-Hong Ignatius Ou et al.   Journal of Thoracic Oncology

Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

(2010) Eunice L. Kwak et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

(2009) Alice T. Shaw et al.   JOURNAL OF CLINICAL ONCOLOGY

RespiFinder: a New Multiparameter Test To Differentially Identify Fifteen Respiratory Viruses

(2008) M. Reijans et al.   JOURNAL OF CLINICAL MICROBIOLOGY